Genelux (GNLX) and Newsoara BioPharma said Tuesday that preliminary data from their co-sponsored ongoing phase 1b/2 small-cell lung cancer study indicated anti-tumor effect from Olvi-Vec immunochemotherapy.
In the initial dose escalation groups, five of the seven evaluable participants for anti-tumor response achieved disease control as the best response, with two of those five exhibiting a partial response, the companies said.
Those five also showed reductions in all of their individual target lesions, according to the companies.
The companies added that Olvi-Vec was "generally well-tolerated with a favorable safety profile."
They said enrollment into dose escalation groups continues to evaluate safety and the recommended intravenous dose for the phase 2 trial of Olvi-Vec, which they said is Genelux's most advanced product candidate.
Price: 3.46, Change: -0.43, Percent Change: -11.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。